Results 91 to 100 of about 35,596 (239)

Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 241-254, January 2026.
Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel, Filippa Schreeck, Simon Jaeger, Severin Schricker, Elke Schaeffeler, Svitlana Igel, Daniela Steinberger, Manuel Pagitz, Jörg Latus, Markus Ketteler, Kerstin Bühl, Marc‐H. Dahlke, Hans‐Georg Kopp, Matthias Schwab   +13 more
wiley   +1 more source

Correlation analysis between CYP2C9 polymorphisms and liver injury induced by flurbiprofen axetil in 100 Han Chinese patients

, 2023
Jiecheng Xiao, Xianwei Wu, Chengfei Zhao
openalex   +1 more source

Artificial Intelligence‐Based In Silico Evaluation of the Pharmacological Potential and In Vitro Anti‐Malignancy Effect in the Human Glioblastoma Cell Line of the Hydrate of the Coumarin Compound Meranzin Originating From the Edible Macroalga (Bangia fuscopurpurea)

Food Science &Nutrition, Volume 14, Issue 1, January 2026.
In U87 cells, meranzin hydrate showed cytotoxicity (MIC = 50 μM) and anti‐invasion activity (IC50 = 33.12 μM) but had no inhibitory effect on colony formation. It also suppressed the cancer stem cell property of sphere formation (IC50 = 21.43 μM). In silico analysis indicated that meranzin hydrate may downregulate the protein expression of ALDH1A1 and ...
Shi‐Ying Huang, Yi‐Chen Chang, Charles Chien‐Chih Chiu, Chang‐Wei Hsieh, Chien‐Wei Feng, Zhi‐Cheng Chen, Nan‐Fu Chen, Yung‐Kuo Lee, Tian‐Huei Chu, Cheng‐Chieh Fang, Nan‐Chieh Huang   +10 more
wiley   +1 more source

Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical Studies

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Miricorilant is a novel selective glucocorticoid receptor (GR) modulator with mixed agonist/antagonist effects at the GR and modest antagonism at the mineralocorticoid receptor that is being developed for the treatment of metabolic dysfunction‐associated steatohepatitis.
Hazel J. Hunt, Kirsteen M. Donaldson, Jeevan R. Kunta, Joseph M. Custodio   +3 more
wiley   +1 more source

A Rational Approach to Pharmacotherapy in Pregnancy

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Most pregnant individuals are exposed to at least one medication, whether prescription or over the counter, during pregnancy. Despite the ubiquity of medication use in pregnancy, there remains no standardized framework to guide clinicians in selecting the most appropriate pharmacotherapy that balances maternal needs with fetal safety. This gap
Gregory W. Kirschen, Kevin Watt, Ahizechukwu C. Eke   +2 more
wiley   +1 more source

Pharmacogenomic Calling From Whole‐Exome Sequencing in the Taiwanese Population—A Real‐World Experience

Molecular Genetics &Genomic Medicine, Volume 14, Issue 1, January 2026.
This study evaluated pharmacogenomic (PGx) calling from whole‐exome sequencing (WES) in 3562 Taiwanese individuals. Fourteen pharmacogenes were reliably identified, with each person carrying an average of ~2.4 actionable phenotypes. The high actionable frequencies of G6PD deficiency and HLA‐B*58:01 highlight ethnic differences and support WES as a ...
Hsu‐Heng Lin, Meng‐Ju Melody Tsai, Hui‐An Chen, Rai‐Hseng Hsu, Yun‐Syuan Lin, Yi‐Lin Lin, Ching Hsu, Yin‐Hsiu Chien, Wuh‐Liang Hwu, Ni‐Chung Lee   +9 more
wiley   +1 more source

Genetic Variations of CYP2C9 in 724 Japanese Individuals and Their Impact on the Antihypertensive Effects of Losartan [PDF]

, 2008
Tong Yin, Keiko Maekawa, Kei Kamide, Yoshiro Saito, Hironori Hanada, Kotaro Miyashita, Yoshihiro Kokubo, Yasuhisa Akaiwa, Ryoichi Otsubo, Kazuyuki Nagatsuka, Toshiho Otsuki, Takeshi Horio, Shin Takiuchi, Yuhei Kawano, Kazuo Minematsu, Hiroaki Naritomi, Hitonobu Tomoike, Jun‐ichi Sawada, Toshiyuki Miyata   +18 more
openalex   +1 more source

Photophysical and DNA‐Binding Properties of Phenoxazine‐Based Push–Pull Type Organic Chromophores: Insights From DFT, Molecular Docking, and Optical Studies

ChemistryOpen, Volume 15, Issue 1, January 2026.
This study investigates the interaction of phenoxazine‐based organic dyads (PO1, PO2, PO4, and PO5) with calf thymus DNA using UV–visible spectroscopy, theoretical HOMO–LUMO analysis, and molecular docking techniques. The results reveal strong DNA‐binding interactions of these dyads, particularly PO5, highlighting their potential in biochemical and ...
Praveen Naik, T Aravinda, Kuruvalli Gouthami, Vaddi Damodara Reddy, B Vinay Kumar, Neela H. Yennawar, Kavya S. Keremane   +6 more
wiley   +1 more source

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
Obesity, MASH and Statins: Insights from a PBPK/PD Zonal Liver Model. ABSTRACT Statins are frequently prescribed for hyperlipidemia, a common comorbidity in patients with obesity and/or metabolic dysfunction‐associated steatohepatitis (MASH). However, limited knowledge exists on how MASH may alter statin disposition within hepatocytes where the statin ...
William A. Murphy, Noora Sjöstedt, Mailys De Sousa Mendes, Mattie Hartauer, Kim L. R. Brouwer, Sibylle Neuhoff   +5 more
wiley   +1 more source

Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT Pediatric extrapolation strategies issued by health authorities have streamlined pediatric drug development and reduced the unnecessary burden of conducting pediatric clinical studies. In line with these strategies, physiologically based pharmacokinetic (PBPK) models have been utilized extensively for initial dosing regimen and sampling ...
James W. T. Yates, Michael Zientek, Kunal S. Taskar, Wen Lin, Tycho Heimbach, Stefan Willmann, Jessica Rehmel, Neil Parrott, Michael Hanley, Justine Badee, Yuan Chen, Susan Cole, Loeckie De Zwart, Sebastian Haertter, Rongrong Jiang, Masakatsu Kotsuma, Guiqing Liang, Yu‐Wei Lin, Jing Liu, Ying Ou, Juliane Rascher, Naveed A. Shaik, Jan Wahlstrom, Xiaofeng Wang, Guangqing Xiao, Ka Lai Yee, S. Y. Amy Cheung   +26 more
wiley   +1 more source